TargED Biopharmaceuticals
PrivateLast Round
Series A
Extension
Jun 24, 2026
Total Funding Raised
$94.98M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
TargED Biopharmaceuticals operates in Healthcare & Life Sciences and is based in Utrecht. Its latest recorded funding round was a Series A Extension round in June 2026.
TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve the treatment of thrombosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TargED Biopharmaceuticals Comparables
Compare TargED Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sanofi | 76% | |
| Takeda | 73% | |
| Omeros Corporation | 72% |
For institutional investors. Book with your work email.
TargED Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jun 24, 2026 | ||||
| Grant | Jun 30, 2025 | ||||
| Series A | Feb 22, 2022 | ||||
| Seed | Nov 30, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TargED Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| Fund+ | Series A Extension, Series A |
| Andera Partners | Series A Extension, Series A |
| European Commission | Series A Extension |
| Inkef Capital | Series A Extension, Series A |
| Hadean Ventures | Series A Extension, Series A |
| BioGeneration Ventures | Series A, Seed, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 1146% MoM, from 26 to 324.
- Jun 24, 2026
$46M round led by Eurazeo, BioGeneration Ventures, and Kurma Partners.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 3, 2026
TargED Biopharmaceuticals attends the American Society of Hematology (ASH) Annual Meeting in Dec '25 and reports positive Phase 1 first-in-human results showing a favorable safety and tolerability profile with no spontaneous bleeding events.
For institutional investors. Book with your work email.
TargED Biopharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TargED Biopharmaceuticals's valuation, stock price, and market status.
Is TargED Biopharmaceuticals a public or private company?
TargED Biopharmaceuticals is a private company.
What is the current stock price of TargED Biopharmaceuticals?
TargED Biopharmaceuticals is a private company, so its shares have no public market price. Caplight tracks TargED Biopharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TargED Biopharmaceuticals worth (valuation)?
Valuation information for TargED Biopharmaceuticals is not publicly available.
Can I buy TargED Biopharmaceuticals stock?
TargED Biopharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TargED Biopharmaceuticals's last funding round?
TargED Biopharmaceuticals's most recent funding round was Series A Extension on June 24, 2026.
Who are the main investors in TargED Biopharmaceuticals?
Key investors in TargED Biopharmaceuticals include Fund+, Andera Partners, Inkef Capital, Hadean Ventures, BioGeneration Ventures.
Will TargED Biopharmaceuticals IPO soon?
No public IPO plans have been announced for TargED Biopharmaceuticals.
How can I track TargED Biopharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in TargED Biopharmaceuticals's shares on secondary markets.